Therefore, we have evaluated the incretin effect using the gold standard protocol of paired frequently sampled oral glucose tolerance tests (OGTT) and matched isoglycemic intravenous glucose infusions (IIGI) in patients with type 2 diabetes treated with acute low-dose sulphonylurea, a condition that does not stimulate insulin secretion markedly. The gene discussed is GCG; the disease is type 2 diabetes mellitus.